Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Samantha Trout

Physician Assistant Kettering, OH Physician Assistant

NPI 1730699109 CMS profile 8466201

3535 Southern Blvd, Kettering, OH 45429

Open in the dashboard

General payments

$8,742

507 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samantha Trout of Kettering, OH is reported in the CMS Open Payments database as having received $8,742 across 507 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,819 188
2024 General $3,732 220
2023 General $2,191 99

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samantha Trout
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Samantha Trout were reported at $2,819. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Samantha Trout Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $2,191 $167 $52–$557 $160
2024 $3,732 $178 $55–$600 $164
2025 $2,819 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $1,156 80 payments
  2. Janssen Biotech, Inc. $1,001 36 payments
  3. Incyte Corporation $767 78 payments
  4. Arcutis Biotherapeutics, Inc. $721 43 payments
  5. Sun Pharmaceutical Industries Inc. $602 35 payments
  6. UCB, Inc. $571 24 payments
  7. Novartis Pharmaceuticals Corporation $513 26 payments
  8. Regeneron Healthcare Solutions, Inc. $504 20 payments
  9. Genzyme Corporation $434 20 payments
  10. LEO Pharma Inc. $311 15 payments
  11. Other $2,162 130 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $8,543 505 payments
  2. Education $199 2 payments
Products named General payments · program years 2023–2025
  1. TREMFYA $995 35 payments
  2. DUPIXENT Immunology $774 32 payments
  3. OPZELURA $767 78 payments
  4. Zoryve $570 39 payments
  5. Winlevi $551 31 payments
  6. Bimzelx $529 22 payments
  7. RINVOQ $525 27 payments
  8. COSENTYX $473 24 payments
  9. SKYRIZI $451 32 payments
  10. DUPIXENT Inflammation And Immunology $429 17 payments
  11. Other $4,452 272 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

477

Median for Physician Assistant: 241

Drug cost

$110,414

Median for Physician Assistant: $4,110

Branded share of claims

2.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 11 $94,783
Fluorouracil Generic 39 $3,956
Pimecrolimus Generic 17 $3,043
Clobetasol Propionate Generic 48 $2,648
Metronidazole Generic 30 $2,226
Ketoconazole Generic 101 $1,191
Clindamycin Phosphate Generic 21 $765
Minocycline Hcl Generic 11 $515
Triamcinolone Acetonide Generic 53 $341
Doxycycline Hyclate Generic 28 $305

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$49,783

Of which drugs: $633

Medicare patients

331

Average age 75

Services billed

1,626

197 women, 134 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 45%
Diabetes 29%
Ischemic heart disease 25%
Chronic kidney disease 25%
Depression 25%
Heart failure 17%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 92 $68

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $549
$549 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $264
  • GENZYME CORPORATION $135
$399 — —
SKYRIZI
  • AbbVie, Inc. $364
$364 — —
OPZELURA
  • Incyte Corporation $331
$331 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $300
$300 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

507 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record